Takeda Pharmaceutical Co Ltd ADR (TAK)
Takeda Pharmaceutical Co Ltd ADR (TAK) carries a ŷRobot AI score of 49 out of 100. The model's fair value estimate is $19.39, 9.5% below the last close of $21.43. The chart signal reads Sell.
| Metric | TAK |
|---|---|
| AI score | 49 / 100 |
| Chart signal | Sell |
| Fair value estimate | $19.39 |
| Upside to fair value | -9.5% |
| Previous close | $21.43 |
| P/E | -61.50 |
| Price / sales | 2.28 |
| Market cap | $67.48B |
| EPS | -0.34 |
| Revenue growth | 2.1% |
| 1-year price change | 0.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about TAK
Is TAK overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates Takeda Pharmaceutical Co Ltd ADR (TAK) at $19.39 against a last close of $21.43, implying 9.5% downside to the model's estimate.
Is TAK's chart signal bullish or bearish?
The chart-signal model classifies TAK as Neutral as of Nov 14, 2026, with a signal score of -0.13 on a -1 to 1 scale.
What is TAK's ŷRobot AI score?
TAK scores 49 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 14, 2026.
Is TAK stock expensive on P/E and P/S?
TAK trades at -61.5 times earnings and 2.3 times sales as of Nov 14, 2026.
What does TAK's seasonal forecast show?
ŷRobot's seasonal forecast curve for TAK reads +1.3% at 30 days, +6.2% at 90 days, and +0.0% at one year as of Nov 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is TAK growing?
Takeda Pharmaceutical Co Ltd ADR's revenue growth is +2.1% and free-cash-flow growth is +186.0% on the latest reported figures.
TAK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.